Parkinson Disease

AGILECT demonstrated improvement in levodopa-treated Parkinson patients

Published in Cancer Weekly, April 5th, 2005

Patients with Parkinson disease (PD) who were optimized on levodopa therapy and other PD therapies experienced a significant reduction in the duration of "off" time, as well as an improvement in motor symptom control during both "on" and "off" periods when once-daily AGILECT (rasagiline tablets) was added to their treatment regimen.

The positive effects seen with once-daily AGILECT were similar to those seen in patients treated with entacapone, given with each levodopa dose, when compared to placebo. The results of the lasting effect in adjunct therapy with rasagiline given once daily (LARGO) study was published in The Lancet.

"Motor...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-04-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry